Dimethyl fumarate associated lymphopenia in clinical practice

被引：34
|
作者：
Longbrake, Erin E. [1 ]
Cross, Anne H. [1 ]
机构：
[1] Washington Univ, Dept Neurol, St Louis, MO 63110 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷 / 06期
关键词：
Dimethyl fumarate; multiple sclerosis; lymphopenia; PLACEBO-CONTROLLED PHASE-3; MULTIPLE-SCLEROSIS; ORAL BG-12; PML;
D O I：
10.1177/1352458514559299
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：796 / 797
页数：2
相关论文
共 50 条
  • [21] Common genetic variation and polygenicity associated with dimethyl fumarate-induced lymphopenia in multiple sclerosis
    Manouchehrinia, Ali
    Kingwell, Elaine
    Carruthers, Robert
    Marrie, Ruth Ann
    Rotstein, Dalia L.
    Evans, Charity
    Jokubaitis, Vilija
    Lechner-Scott, Jeannette
    Maltby, Vicki
    Zhong, Michael
    Wright, Galen
    Drogemoller, Britt
    Maruf, Abdullah
    Kuan, Annie
    Levin, Michael
    MacIsaac, Julie
    Luo, Wenzhuo
    Desrochers, Brianne
    Luo, Daniel
    Andlauer, Till
    Hemmer, Bernhard
    Bernatsky, Sasha
    Kobor, Michael
    Tremlett, Helen
    Kowalec, Kaarina
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 608 - 609
  • [22] Persistent lymphopenia after routine clinical use of dimethyl fumarate for relapsing remitting multiple sclerosis
    MacDougall, N. J.
    Gallagher, P.
    Murdoch, S.
    Murray, L.
    Webb, S.
    Overell, J. R.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 300 - 300
  • [23] Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate
    Wood, Callum H.
    Robertson, Neil P.
    Htet, Zin Min
    Tallantyre, Emma C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [24] Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature
    Russo, Cinzia Dello
    Scott, Kathryn Anne
    Pirmohamed, Munir
    PHARMACOLOGY & THERAPEUTICS, 2021, 219
  • [25] Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, Maryam
    Barilla, David
    Lee, Chieh-Hsin
    Blevins, Gregg
    Giuliani, Fabrizio
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2018, 5 (02):
  • [26] Effect of dimethyl fumarate on lymphocytes in RRMS Implications for clinical practice
    Mehta, Devangi
    Miller, Catherine
    Arnold, Douglas L.
    Bame, Eris
    Bar-Or, Amit
    Gold, Ralf
    Hanna, Jerome
    Kappos, Ludwig
    Liu, Shifang
    Matta, Andre
    Phillips, J. Theodore
    Robertson, Derrick
    von Hehn, Christian A.
    Campbell, Jordana
    Spach, Karen
    Yang, Lili
    Fox, Robert J.
    NEUROLOGY, 2019, 92 (15) : E1724 - E1738
  • [27] Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate
    Dempsey, John Patrick
    Wu, Lisa
    Balshi, Alexandra
    Jun, Claire
    Baber, Ursela
    Sloane, Jacob A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 89
  • [28] Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes
    Dinoto, Alessandro
    Sartori, Arianna
    Cheli, Marta
    Pasquin, Fulvio
    Baldini, Sara
    Bratina, Alessio
    Bosco, Antonio
    Manganotti, Paolo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [29] Age influences lymphopenia in MS patients treated with dimethyl-fumarate
    Mancinelli, C. R.
    Scarpazza, C.
    Rasia, S.
    De Rossi, N.
    Cordioli, C.
    Capra, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 506 - 507
  • [30] Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation
    Caldito, Natalia Gonzalez
    O'Leary, Shirley
    Stuve, Olaf
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (08) : 1306 - 1308
12345